2 recruiting, 1 completed, 1 terminated. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Completed 1, Terminated 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow ImmunoGenesis: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab Evofosfamide, Zalifrelimab, Balstilimab - Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | ImmunoGenesis | 71 | 2025-01-08 | 2025-01-21 |
| Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors IMGS-001 - Solid Tumor | Phase 1 | Recruiting | ImmunoGenesis | 105 | 2023-09-07 | 2026-09-04 |
| Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer TH-302, Nab-paclitaxel, Gemcitabine - Pancreatic Cancer | Phase 1 | Terminated | ImmunoGenesis | 19 | 2014-01-01 | 2025-05-11 |
| Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma TH-302 - Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | ImmunoGenesis | 107 | 2008-08-01 | 2025-05-13 |
Pancreatic Neoplasms (2) · Prostatic Neoplasms (1) · Sarcoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
TH 302 (3) · 130-nm albumin-bound paclitaxel (1) · Gemcitabine (1) · balstilimab (1)
United States (4)